Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Acamprosate
Treatment for Alcohol use disorders
Typical Dosage: 666mg three times daily (total 1998mg/day)
Effectiveness
35%
Safety Score
72%
Clinical Trials
12
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
666mg three times daily (total 1998mg/day)
Time to Effect
2-4 weeks
Treatment Duration
6-12 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$1,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$3,714
Cost per Remission
$5,200
Prescription Access Economics
Annual Societal Loss per Patient
$880
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$500/year
Time Cost
$140/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$800/year
Potential OTC Price
$300/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWAcamprosate Outcomes
for Alcohol use disorders
Efficacy Outcomes
Overall Effectiveness
+35%
Response Rate
+35%
Remission Rate
+25%
Common Side Effects
Diarrhea
+18%
Nausea
+8%
Abdominal pain
+7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Acamprosate in Alcohol use disorders
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
NCT06269627RECRUITINGPHASE4
48 participants
INTERVENTIONAL
Bethesda, United States
Started: May 7, 2025
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease
NCT07553377NOT YET RECRUITINGNA
50 participants
INTERVENTIONAL
New Haven, United States
Started: Oct 1, 2027
Combining a Smartphone App With Medications to Manage Heavy Drinking
NCT06303778RECRUITINGNA
330 participants
INTERVENTIONAL
Phoenix, United States +14 more
Started: Nov 1, 2024
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
NCT07060638RECRUITINGPHASE2
216 participants
INTERVENTIONAL
Indianapolis, United States +5 more
Started: Jan 27, 2026
Completed Clinical Trials
6 completed trials for Acamprosate in Alcohol use disorders
Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
NCT03818191COMPLETEDPHASE4
288 participants
INTERVENTIONAL
Center City, United States +2 more
Started: Jul 15, 2019
Acamprosate Initiated During Alcohol Detoxification
NCT00360594COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Philadelphia, United States
Started: Oct 1, 2006
Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations
NCT06471686COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Los Angeles, United States
Started: Dec 1, 2021
Open Label Trial of Acamprosate in Bipolar Alcoholics
NCT00330486COMPLETEDPHASE1, PHASE2
9 participants
INTERVENTIONAL
Charleston, United States
Started: Apr 1, 2006
Acamprosate in Alcoholics With Comorbid Anxiety or Depression
NCT00330174COMPLETEDPHASE4
90 participants
INTERVENTIONAL
Belmont, United States +2 more
Started: Apr 1, 2006
Acamprosate Safe to Use in Individuals With Liver Disease.
NCT04287920COMPLETEDPHASE2
12 participants
INTERVENTIONAL
Rochester, United States
Started: Sep 21, 2020